Mileutis is in advanced stages of development of an innovative product which addresses bovine mastitis, the main concern in the dairy industry. Israeli animal health company Mileutis Ltd. has received a $20 million investment from US life sciences and healthcare investor NovaQuest Capital Management LLC, as part of a product financing agreement. Ness Ziona-based Mileutis is a biopharmaceutical company developing a product to help mitigate the use of antibiotics in animals and NovaQuest’s investment will support the continued development and commercialization of Mileutis’ novel, biologically sourced, and residue-free therapies for animal health. NovaQuest’s investment is its first ever in the animal health care field and in an Israeli company. Mileutis was represented by Adv. Gary Copelovitz, Head of our International Department.